Gene expression profiles of MRD vs diagnostic MM clonal PCs. (A) Heat map of genes with differential expression (false discovery rate q-value <0.05) between patient-paired diagnostic and MRD clonal PCs. (B) Overall survival according to low vs high (≤10.29 vs >10.29 normalized mRNA expression) ALCAM levels determined in CD138^+ve purified PCs from newly diagnosed MM patients treated according to TT3A (n = 276; training set) and TT3B (n = 168; validation set). (C) ALCAM (CD166) protein surface expression in a panel of MM cell lines is shown using the total density graphic representation of the Infinicyt software. (D) Overall ALCAM (CD166) protein surface expression in chemoresistant (Annexin-V^−ve) and apoptotic (Annexin-V^+ve) RPMI-8226 cells; the percentage of ALCAM^−ve and ALCAM^+ve MM cells is represented by the black and gray bars, respectively. (E) Percentage of ALCAM^−ve cells within total chemoresistant (Annexin-V^−ve) RPMI-8226 cells at baseline, on coculture with BMSCs and in coculture with BMSCs after 24- and 48-hour exposure to bortezomib, lenalidomide, dexamethasone, and melphalan. All experiments were performed in triplicate. (F) Representative experiment (n = 1) of ALCAM (CD166) protein surface expression in chemoresistant (Annexin-V^−ve) RPMI-8226 cells.